



## 100,000 PATIENTS TREATED WITH IBA PROTON THERAPY TECHNOLOGY

**Important milestone demonstrates the unrivalled experience, technological innovation and global market leadership of IBA and its clinical partners**

**Louvain-la-Neuve, Belgium, 25 September 2020** - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, is pleased to announce that more than 100,000 patients have now been treated with IBA proton therapy systems around the world. This is an important milestone that marks a step towards IBA's mission to make proton therapy available to all patients who could benefit from it, by providing healthcare professionals with the most advanced, high performance proton therapy solutions. This milestone is a proud moment for IBA's employees and clinical partners around the world as they remain united in their efforts to maximize the positive impact on cancer patients' lives.

**Olivier Legrain, Chief Executive Officer at IBA, commented:** "We are immensely proud that IBA's technology has impacted 100,000 lives, giving patients and their families a new hope for the future. Reaching this milestone would not have been possible without the commitment of our employees and the close relationships that we have continued to build with our clients and partners over the last 30 years. Our common goal is to make proton therapy accessible to a greater number of patients, and we believe that our passion, energy and expertise will enable us to achieve this. We continue to pursue further innovation by developing new technologies that will allow us to provide increasingly high standards while reducing treatment costs. I would like to offer my warmest thanks to our partners and employees for their efforts to protect, enhance and save lives."

**Proton therapy is one of the most promising forms of cancer therapy** and is considered the most advanced form of radiotherapy in cancer treatments. Proton therapy makes it possible to target tumors with better precision, minimizing radiation exposure of the surrounding healthy tissue and thereby improving the quality of life of patients during and after treatment

**The clinical benefits of proton therapy are increasingly acknowledged.** As the number of patients being treated with proton therapy continues to grow, appreciation of the effectiveness of the technology is also increasing within the medical community. A large number of clinical studies are currently ongoing and their results have the potential to open a new era for proton therapy treatment.

**Proton therapy is becoming more and more accessible to a growing number of patients throughout the world.** IBA has invested substantial resources in researching and developing new approaches to minimize the cost of proton therapy and make it more accessible to the maximum number of cancer patients. IBA's Proteus<sup>®</sup>ONE compact single room solution is game changing with regard to making the treatment more accessible, whilst retaining the latest technological capabilities in proton therapy.



**IBA continues to invest in the research and development of innovative technological solutions to further advance its proton therapy offering.** The technological roadmap of IBA is focused on three areas: Motion Management, Arc Therapy\*\* and FLASH\*\* Irradiation. IBA constantly looks to improve the proton therapy technology for the benefit of patients, in close collaboration with its customers and industrial partners.

**The largest and most experienced proton therapy community.** With 36 centers treating patients in 86 rooms, and another 20 centers in development, IBA's user community is unrivalled. This unique experience from IBA clinical partners coupled with IBA's unique technological expertise and open partnership philosophy ideally positions the company to continue to lead innovation in proton therapy.

**\*\*\*Ends\*\*\***

### **About Proton Therapy**

Proton therapy is considered to be the most advanced form of radiotherapy in the fight against cancer. The unique dose deposition that proton therapy offers enables the tumor to be targeted more effectively than other treatments. Compared to photon radiotherapy, protons deposit almost all their energy within a controlled zone and, in the vast majority of cases, limit the amount of the dose deposited in the healthy tissue surrounding the tumor. The use of protons consequently offers the potential to reduce the secondary effects of the treatment.

### **About IBA**

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

*\* Proteus®ONE is the brand name of Proteus®235.*

*\*\* ARC therapy is work in progress and FLASH therapy is currently under research. They are not available for sale.*



**For further information, please contact:**

**IBA**

**Aymeric Harmant**

Global Marketing Proton Therapy Director

+32 475 940 975

[aymeric.harmant@iba-group.com](mailto:aymeric.harmant@iba-group.com)